Human Herpesvirus 2

Dosage for Human Herpesvirus 2 extract is highly individualized and depends entirely on the purpose of the test (diagnostic vs. assessment of immunity) and the patient's sensitivity history.

• Scratch or Prick Testing: A single drop of the concentrated extract (typically 1:10 or 1:20 w/v) is applied to the skin, followed by a superficial puncture.
• Intradermal Testing: If the prick test is negative, a more sensitive intradermal test may be performed. The standard dose is 0.02 mL to 0.05 mL of a 1:100 or 1:1000 dilution, injected into the superficial layers of the skin to create a small bleb (6-10 mm).
• Immunity Assessment: When used as a recall antigen, a standard dose of 0.1 mL of a specific PNU concentration is often utilized, similar to a Tuberculin (PPD) test.

Human Herpesvirus 2 extract is not commonly approved for routine pediatric use unless specifically indicated by a pediatric immunologist. In children, the skin's reactivity may be different, and the risk of a systemic reaction must be weighed against the diagnostic benefit. If used, the dosage is usually identical to the adult intradermal dose (0.02 mL), but the clinician may opt for higher dilutions (e.g., 1:10,000) to ensure safety. Only a specialist should perform these tests in children under 12 years of age.

Renal Impairment

No dosage adjustment is required for patients with renal impairment, as the extract is a biological protein processed locally and via the lymphatic system rather than being cleared by the kidneys.

Hepatic Impairment

No dosage adjustment is necessary for patients with hepatic impairment. The metabolism of viral antigens does not involve hepatic pathways.

Elderly Patients

Elderly patients may exhibit 'skin anergy' (reduced skin reactivity) due to the natural aging of the immune system. While the dose remains the same, the interpretation of the results must be cautious, as a negative result may not necessarily indicate a lack of immunity but rather a diminished skin response.

This medication is NEVER self-administered. It must be administered by a healthcare professional in a clinical setting equipped with emergency resuscitation equipment.

1. 1Preparation: The skin (usually the volar surface of the forearm) is cleaned with alcohol.
2. 2Administration: The extract is injected intradermally using a short, fine-gauge needle (26G or 27G). The needle bevel should face upward.
3. 3Observation: After the injection, the patient must remain in the clinic for at least 30 minutes to be monitored for signs of anaphylaxis (a severe, life-threatening allergic reaction).
4. 4Reading the Test: For immediate reactions, the site is measured at 15-20 minutes. For delayed reactions, the patient must return to the clinic in 48 to 72 hours for the clinician to measure the diameter of the induration (not the redness).
5. 5Storage: The vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze, as freezing can denature the proteins and render the extract ineffective.

Since this is a diagnostic test administered by a professional, missed doses are generally not an issue. If a patient misses their follow-up appointment to read the test (at 48-72 hours), the test may need to be repeated on the opposite arm, as the window for accurate measurement will have passed.

An 'overdose' in the context of an allergenic extract refers to the administration of a concentration that is too high for the patient's sensitivity level.

• Signs: Massive local swelling, severe itching, or systemic symptoms such as hives, wheezing, swelling of the throat, and a drop in blood pressure.
• Emergency Measures: If a systemic reaction occurs, the immediate administration of Epinephrine (1:1000) via intramuscular injection is required. Antihistamines and corticosteroids may also be used as secondary treatments.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Ensure you inform your doctor of any previous severe reactions to skin tests.

Most patients receiving Human Herpesvirus 2 extract will experience some form of local reaction, which is often the intended result of the diagnostic test.

• Local Erythema (Redness): A red patch around the injection site is very common. It may feel warm to the touch and usually appears within minutes or hours.
• Pruritus (Itching): Intense itching at the site of injection is common as the body releases histamine in response to the viral proteins. This typically subsides within 24 hours.
• Induration (Hardening): In a positive delayed-type hypersensitivity test, a hard bump will form. This may feel slightly tender or uncomfortable.
• Local Edema (Swelling): Swelling at the site (the 'wheal') is expected and usually resolves within a few hours for immediate tests.

• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit if the test was on the arm) may occur as the immune system processes the antigen.
• Persistent Discoloration: The skin at the injection site may remain slightly darker or lighter than the surrounding skin for several weeks.
• Malaise: Some patients report feeling generally unwell, tired, or 'flu-like' for 24 hours following the administration of the extract.

• Secondary Infection: As with any injection, there is a small risk of introducing bacteria into the skin, leading to cellulitis (a skin infection) or a small abscess.
• Scarring: If the local reaction is particularly severe (ulceration), a small permanent scar may form at the site.
• Vasovagal Syncope: Fainting or feeling lightheaded due to the needle stick or the sight of the reaction.

> Warning: Stop taking Human Herpesvirus 2 and call your doctor immediately if you experience any of these symptoms of a systemic allergic reaction:

• Anaphylaxis: This is a medical emergency characterized by a rapid onset of symptoms across multiple organ systems. Look for a combination of hives, difficulty breathing, and feeling faint.
• Angioedema: Severe swelling under the skin, particularly around the lips, eyes, or tongue, which can obstruct the airway.
• Bronchospasm: Sudden wheezing, chest tightness, or shortness of breath occurring shortly after the injection.
• Hypotension: A dangerous drop in blood pressure that may cause the patient to collapse or lose consciousness.
• Generalized Urticaria: Hives that spread across the entire body, not just at the injection site.

Because Human Herpesvirus 2 extract is used for diagnostic purposes and is not a chronic medication, long-term side effects are extremely rare. There is no evidence that a single skin test increases the risk of developing herpes simplex virus infections or any chronic autoimmune conditions. However, repeated testing over many years could theoretically lead to 'sensitization,' where the patient becomes more allergic to the extract over time.

While many allergenic extracts carry a general warning regarding anaphylaxis, non-standardized extracts like Human Herpesvirus 2 must be used with the understanding that their potency is not standardized.

FDA-Required Warning Summary: This product can cause severe systemic allergic reactions, including fatal anaphylaxis. It should only be administered by physicians who are exceptionally experienced in the treatment of systemic allergic reactions and in facilities where the necessary equipment and medications (such as epinephrine) are immediately available. Patients with unstable asthma are at a higher risk for severe reactions.

Report any unusual symptoms to your healthcare provider. Even a small local reaction that seems to be spreading should be reported.

Human Herpesvirus 2 extract is a potent biological material. It is intended only for diagnostic use and must never be injected intravenously. Patients must be screened for a history of severe allergic reactions to previous skin tests or to any components of the extract, such as phenol. If you have a known allergy to the Herpes Simplex Virus itself, you must inform your doctor, as the skin test could trigger a significant localized or systemic response.

No specific FDA black box warning is unique to 'Human Herpesvirus 2' as an individual agent, but it falls under the General Black Box Warning for Allergenic Extracts. This warning states that allergenic extracts may cause severe life-threatening systemic reactions. Patients should be observed for at least 30 minutes after administration. Those with severe or unstable asthma, or those taking beta-blockers, may be at increased risk and may be more difficult to treat if a reaction occurs.

• Allergic Reactions / Anaphylaxis Risk: The primary risk is an IgE-mediated systemic reaction. This is more likely if the patient is highly sensitive or if the extract is injected into a highly vascular area.
• Asthma Exacerbation: Patients with active asthma symptoms should not undergo skin testing until their asthma is well-controlled. A systemic reaction to the extract can trigger a severe asthma attack.
• Skin Conditions: Testing should not be performed on skin areas with active dermatitis, eczema, or psoriasis, as these conditions can lead to false-positive results or interfere with the reading of the test.
• Immunocompromised Patients: In patients with severe immunodeficiency, the skin test may be 'negative' even if the patient has been exposed to the virus. This is known as anergy and must be interpreted carefully by the clinician.

• Immediate Observation: Vital signs (blood pressure, heart rate, and respiratory rate) should be monitored if the patient shows any signs of distress during the 30-minute post-injection waiting period.
• Site Monitoring: The patient should be instructed to monitor the injection site at home for the next 72 hours and report any swelling that exceeds the size of a silver dollar or any signs of infection (pus, increasing pain, or fever).

Human Herpesvirus 2 extract generally does not affect the ability to drive or operate machinery. However, if a patient experiences a vasovagal reaction (fainting) or a systemic allergic reaction, they should not drive until they have fully recovered and been cleared by a medical professional.

There are no known direct interactions between alcohol and Human Herpesvirus 2 extract. However, alcohol can cause vasodilation (opening of the blood vessels), which might theoretically increase the rate of absorption of the extract or worsen a local 'flare' reaction. It is advisable to avoid heavy alcohol consumption on the day of the test.

As this is a one-time diagnostic tool, 'discontinuation' does not apply in the traditional sense. However, if a patient has a severe reaction to the first step of a multi-step skin test (e.g., the prick test), the subsequent steps (e.g., the intradermal test) must be cancelled immediately.

> Important: Discuss all your medical conditions with your healthcare provider before starting Human Herpesvirus 2. Ensure they are aware of any history of fainting during medical procedures.

There are no drugs that are strictly 'contraindicated' in a way that causes a fatal chemical reaction with HHV-2 extract. However, certain drugs make the test dangerous or impossible to interpret:

• Beta-Blockers (e.g., Propranolol, Atenolol): These are considered a relative contraindication. If a patient on a beta-blocker has an anaphylactic reaction to the HHV-2 extract, the standard treatment (Epinephrine) may be ineffective, leading to a potentially fatal outcome.

• ACE Inhibitors (e.g., Lisinopril): These medications may increase the risk of severe flushing and low blood pressure during a systemic reaction to an allergenic extract.
• Systemic Corticosteroids (e.g., Prednisone): High doses of steroids can suppress the T-cell mediated response, leading to a false-negative result in a delayed-type hypersensitivity test. Generally, patients should be off systemic steroids for at least 1-2 weeks before testing if the goal is to assess immune competence.

• Antihistamines (H1 Blockers like Cetirizine, Loratadine, Diphenhydramine): These drugs directly block the 'wheal and flare' response. If a patient takes an antihistamine within 3-7 days of the test, the results will be invalid. This is a pharmacodynamic interaction where the drug masks the body's natural response to the antigen.
• Tricyclic Antidepressants (e.g., Amitriptyline): These medications have potent antihistamine properties and can suppress skin reactivity for up to two weeks.
• H2 Blockers (e.g., Famotidine): While less potent than H1 blockers, they can also contribute to a reduced skin response and should be discontinued 48 hours prior to testing.

There are no specific food interactions with Human Herpesvirus 2 extract. However, patients should avoid consuming foods they are known to be highly allergic to on the day of the test, as this could prime the immune system and increase the risk of a systemic reaction to the viral extract.

• St. John's Wort: While primarily known for CYP450 interactions, its effect on overall immune modulation is poorly understood; patients should inform their doctor if they are taking it.
• High-dose Vitamin C: Some studies suggest Vitamin C may have mild antihistamine effects, which could theoretically dampen a skin test reaction.

• Other Skin Tests: If multiple skin tests are performed simultaneously (e.g., HHV-2, Mumps, and Candida), the reactions may overlap, making it difficult to read the results.
• TB Tests (PPD): Administering HHV-2 extract at the same time as a Tuberculin skin test is generally acceptable, but they must be placed at least 5 cm apart to avoid cross-contamination of the inflammatory response.

For each major interaction, the management strategy is usually to discontinue the interfering medication for a specific period (washout period) before the test is performed. Always provide a full list of your medications to your allergist.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Do not stop taking prescribed medications without consulting the prescribing physician first.

Human Herpesvirus 2 extract must NEVER be used in the following circumstances:

• Previous Severe Systemic Reaction: If a patient has ever experienced anaphylaxis or a severe systemic reaction to HHV-2 extract or any similar viral extract, further testing is strictly prohibited.
• Known Hypersensitivity to Phenol: Since most non-standardized extracts use phenol as a preservative, a known allergy to phenol is an absolute contraindication.
• Acute Viral Infection: Testing should not be performed during an active, febrile (fever-producing) illness, as the immune system is already stressed, and the test results will be unreliable.

These are conditions where the doctor must weigh the benefits against the risks:

• Unstable Asthma: If a patient's FEV1 (forced expiratory volume) is less than 70% of their predicted value, the risk of a severe reaction is significantly higher.
• Pregnancy: While not strictly forbidden, skin testing is usually deferred during pregnancy to avoid the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen to the baby).
• Beta-Blocker Therapy: As mentioned, this makes treating a potential reaction much more difficult.
• Active Skin Disease: Generalized urticaria or severe dermatitis at the site of testing.

Patients who are highly sensitive to other members of the Herpesviridae family, such as Human Herpesvirus 1 (HSV-1) or Varicella-Zoster Virus (VZV), may show cross-reactivity to the HHV-2 extract. This is because these viruses share similar protein structures in their envelopes. A positive reaction to HHV-2 may actually be a cross-reaction from a previous shingles or cold sore infection.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Human Herpesvirus 2. Be honest about all past allergic reactions, even those that seemed minor.

Human Herpesvirus 2 extract is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm or affect reproduction capacity. The primary concern during pregnancy is not the extract itself, but the risk of a systemic allergic reaction (anaphylaxis). Anaphylaxis in the mother can lead to a sudden drop in blood pressure, which reduces blood flow to the placenta and can cause fetal distress or even fetal death. Therefore, skin testing with HHV-2 extract is typically avoided during pregnancy unless the diagnostic information is considered critical for the mother's health.

It is not known whether the antigenic components of HHV-2 extract or the preservative (phenol) are excreted in human milk. Because the dose used in skin testing is extremely small and the proteins are processed locally, it is unlikely that a significant amount would reach the nursing infant. However, as a precaution, healthcare providers may recommend monitoring the infant for any unusual skin rashes if the mother undergoes testing while breastfeeding.

Safety and effectiveness in the pediatric population have not been formally established through rigorous clinical trials. In children, the immune system is still developing, and skin reactivity may not reach adult levels until after age 5. If testing is required, it should be performed by a specialist. There is no evidence that HHV-2 extract affects growth or development in children.

Clinical studies of non-standardized allergenic extracts generally do not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. In geriatric patients, the skin often becomes thinner and loses elasticity, which can make the 'wheal' of a skin test harder to see. Additionally, the T-cell response (delayed hypersensitivity) naturally declines with age (immunosenescence). Doctors should consider these factors when interpreting a 'negative' result in an elderly patient.

Patients with end-stage renal disease (ESRD) often exhibit a state of 'uremic immune suppression.' This can lead to false-negative results in delayed-type hypersensitivity testing. While the dose does not need to be adjusted, the clinical interpretation must account for the patient's renal status. Dialysis does not clear the extract from the body.

There are no specific concerns regarding hepatic impairment and the use of HHV-2 extract. The liver is not involved in the processing of these intradermal proteins.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant or planning to become pregnant before any diagnostic procedure.

Human Herpesvirus 2 extract functions as a complex biological antigen. The extract contains viral proteins, primarily glycoproteins G, B, and D, which are located on the viral envelope. When these proteins are introduced into the skin, they act as 'non-self' signals to the immune system.

The primary mechanism for diagnostic use is the Type IV Hypersensitivity Reaction. This involves the activation of sensitized T-lymphocytes. Upon re-exposure to HHV-2 antigens, these T-cells undergo clonal expansion and secrete pro-inflammatory cytokines. This leads to the recruitment of mononuclear cells (monocytes and lymphocytes) to the injection site, creating the characteristic firm swelling known as induration. This response is a direct measure of the 'memory' of the adaptive immune system.

• Dose-Response: There is a clear dose-response relationship; higher concentrations of the extract will produce larger wheals or indurations, up to a plateau point.
• Time to Onset: Immediate (IgE) reactions occur within 15-30 minutes. Delayed (T-cell) reactions occur within 24-48 hours and peak at 72 hours.
• Duration of Effect: The physical reaction typically resolves within 5-7 days as the inflammatory mediators are dissipated and the recruited cells migrate away from the site.
• Tolerance: Repeated skin testing in a short period can lead to 'tachyphylaxis' or a diminished response, as local immune resources are temporarily exhausted.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local administration) |

| Protein Binding | High (to local tissue proteins) |

| Half-life | 2-4 hours (protein degradation) |

| Tmax | 15 min (Immediate) / 48 hrs (Delayed) |

| Metabolism | Local Proteolysis |

| Excretion | Lymphatic Clearance |

• Molecular Formula: Complex mixture of viral proteins and lipids.
• Molecular Weight: Varies (Glycoprotein D is approx. 50-60 kDa).
• Solubility: Soluble in buffered saline solutions.
• Description: A clear to slightly turbid liquid, often containing 0.4% phenol as a preservative.

Human Herpesvirus 2 extract is classified as a Non-Standardized Allergenic Extract. It is part of a broader group of biological products that includes fungal extracts (like Candida albicans), plant extracts (like Ragweed), and other viral antigens. These products are regulated under the Biologics License Application (BLA) pathway by the FDA's Center for Biologics Evaluation and Research (CBER).